In a recent regulatory filing submitted to the Securities and Exchange Commission, NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) disclosed that Chief Financial Officer Keithly Garnett has acquired additional shares of the company's common stock. According to the Form 4 documentation, the transaction took place on April 15, 2025.
Mr. Garnett purchased 300 shares at a price point of $5.38 per share, representing a total investment value of $1,614. Since this purchase, the stock has experienced downward pressure; it is currently trading at $4.78, which is an approximate decline of 11% from the executive's recent acquisition price. This movement follows a broader trend of share price depreciation, with the stock having fallen roughly 46% over a six-month period. Notably, analysis regarding the Relative Strength Index (RSI) indicates that the stock is currently in oversold territory.
Ownership Structure and Holdings
Following this latest transaction, Mr. Garnett's direct ownership of NeOnc Technologies common stock stands at 241,200 shares. Beyond his direct holdings, he maintains beneficial ownership of an additional 44,053 shares through indirect channels. These indirect interests are held via HCWG LLC. The ownership chain involves Mr. Garnett as the sole member of The Hilkiah Group LLC, which holds a 4.3% interest in HCWG LLC, the entity that serves as the direct holder of those shares.
Corporate Developments and Financial Activity
The insider purchase arrives amidst several recent operational and financial updates for NeOnc Technologies. The company recently secured approximately $16 million through a private placement involving the sale of warrants and shares under a securities purchase agreement. In terms of leadership, David Choi has been appointed as the Chief Accounting Officer, tasked with overseeing the organization's financial reporting and accounting functions.
In legal matters, NeOnc Technologies reached a settlement regarding a dispute with Fox Infused, LLC. The agreement involves a payment of $737,920.77 following the termination of an earlier agreement with the entity earlier this year. Furthermore, BTIG has initiated coverage on the company with a buy rating, specifically noting NeOnc's strategic focus on advancing treatments for tumors within the central nervous system.
Clinical Pipeline and Future Outlook
Looking ahead to clinical milestones, the company has scheduled the presentation of initial data from its Phase 1/2 clinical trial, known as NEO212-01, for March 2026. This trial focuses on a bioconjugated temozolomide platform and is expected to provide findings regarding toxicity, safety, and pharmacokinetics.
Key Market Observations
- Insider Confidence: The direct purchase by the CFO provides a data point regarding internal valuation perceptions during a period of stock decline.
- Capital Position: The successful $16 million private placement highlights recent efforts to bolster liquidity through securities sales.
- Clinical Focus: The company's direction is heavily tied to its bioconjugated temozolomide platform and upcoming 2026 data presentations in the biotech sector.
Risks and Uncertainties
- Market Volatility: The significant 46% decline in share price over six months illustrates high volatility within the stock's recent history.
- Clinical Dependency: Future progress is closely linked to the March 2026 presentation of NEO212-01 clinical trial data, including safety and pharmacokinetic results.
- Legal and Operational Costs: The settlement with Fox Infused, LLC involving a payment of $737,920.77 represents a recent financial outflow following the termination of their agreement.